Was there enough data to support the area under the curve/MIC target and inferred troughs recommended in the guidelines? Is it always correct to dose based on actual bodyweight? Do clinicians ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed ... and has been administered in a twice-daily dosing regimen in clinical trials without the need for ...

The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...